(Total Views: 572)
Posted On: 11/11/2025 9:49:40 AM
Post# of 158772
Another treatment is setting the bar for mCRC treatment in a phase 1 trial, with only 12 patients. Lyell Immunotherapy gets the rights for cheap.
Lyell Immunotherapy buys rights to CAR-T cell treatment for metastatic Colorectal Cancer.
The biotech pointed to the “impressive results” that the therapy’s creator, U.S.- and China-based Innovative Cellular Therapeutics, saw in an ongoing U.S. study in 12 patients with refractory metastatic colorectal cancer. That phase 1 trial has so far shown a 67% overall response rate, an 83% disease control rate and median progression-free survival of 7.8 months in the highest dose tested, Lyell noted in its Nov. 10 release.
Lyell signs deal for phase 1-stage colorectal cancer CAR-T https://share.google/0JtzCQWqpAVTGCt2s
Lyell Immunotherapy buys rights to CAR-T cell treatment for metastatic Colorectal Cancer.
The biotech pointed to the “impressive results” that the therapy’s creator, U.S.- and China-based Innovative Cellular Therapeutics, saw in an ongoing U.S. study in 12 patients with refractory metastatic colorectal cancer. That phase 1 trial has so far shown a 67% overall response rate, an 83% disease control rate and median progression-free survival of 7.8 months in the highest dose tested, Lyell noted in its Nov. 10 release.
Lyell signs deal for phase 1-stage colorectal cancer CAR-T https://share.google/0JtzCQWqpAVTGCt2s
(4)
(0)
